Nevro gets FDA nod for diabetic neuropathy treatment but misses Q2 sales target

Retrieved on: 2021-07-20 14:15:00

Tags for this article:

Click the tags to see associated articles and topics

Nevro gets FDA nod for diabetic neuropathy treatment but misses Q2 sales target. View article details on hiswai:

Excerpt

As analysts at Truist Securities said in a note to investors, Nevro management has previously suggested 25% to 30% of covered lives would be ...

Article found on: www.medtechdive.com